The AMCP Format for Formulary Submissions

Welcome to version 4.0

The AMCP Format Executive Committee

Research output: Contribution to journalComment/debate

3 Citations (Scopus)

Abstract

Managed care pharmacists are increasingly presented with complex considerations related to prescription drug formulary management. As prescription drug spending soars, and new effective, but expensive drugs rush to the market, pharmacists and other health care decision makers must evaluate a myriad of important clinical and economic considerations in determining the relative value and, subsequently, the appropriate placement of a product within a formulary. The AMCP Format for Formulary Submissions, Version 4.0, is the next iteration of the Format, which was first released in 2000. Version 4.0, developed by pharmacists from health plan, manufacturer, and academic perspectives, provides updated recommendations on acquiring and evaluating clinical and economic evidence to inform formulary and medical policy decisions. It also includes new guidance related to emerging special topic considerations such as biosimilars, specialty pharmacy products, and companion diagnostic tests. Version 4.0 has been modified to improve the usability of the Format, with clarifying guidance related to logistical considerations such as a recommended time frame for implementation of Version 4.0, as well as dossier updates and ongoing communication between manufacturers and health care decision makers. The Format should be used as a framework for ongoing evidencebased dialogue between manufacturers and payers. The evolving health care landscape will require new levels of collaboration and communication among key stakeholders to successfully navigate the challenges of this new environment. The Format provides a framework to support these critical interactions related to product value by facilitating an evidence-based, transparent approach.

Original languageEnglish (US)
Pages (from-to)444-446
Number of pages3
JournalJournal of Managed Care and Specialty Pharmacy
Volume22
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Formularies
Health care
Prescription Drugs
Pharmacists
Biosimilar Pharmaceuticals
Delivery of Health Care
Economics
Communication
Managed Care Programs
Routine Diagnostic Tests
Health
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science
  • Health Policy

Cite this

The AMCP Format for Formulary Submissions : Welcome to version 4.0. / The AMCP Format Executive Committee.

In: Journal of Managed Care and Specialty Pharmacy, Vol. 22, No. 5, 01.05.2016, p. 444-446.

Research output: Contribution to journalComment/debate

The AMCP Format Executive Committee. / The AMCP Format for Formulary Submissions : Welcome to version 4.0. In: Journal of Managed Care and Specialty Pharmacy. 2016 ; Vol. 22, No. 5. pp. 444-446.
@article{0b088487393d42469e6f5627f1a876d4,
title = "The AMCP Format for Formulary Submissions: Welcome to version 4.0",
abstract = "Managed care pharmacists are increasingly presented with complex considerations related to prescription drug formulary management. As prescription drug spending soars, and new effective, but expensive drugs rush to the market, pharmacists and other health care decision makers must evaluate a myriad of important clinical and economic considerations in determining the relative value and, subsequently, the appropriate placement of a product within a formulary. The AMCP Format for Formulary Submissions, Version 4.0, is the next iteration of the Format, which was first released in 2000. Version 4.0, developed by pharmacists from health plan, manufacturer, and academic perspectives, provides updated recommendations on acquiring and evaluating clinical and economic evidence to inform formulary and medical policy decisions. It also includes new guidance related to emerging special topic considerations such as biosimilars, specialty pharmacy products, and companion diagnostic tests. Version 4.0 has been modified to improve the usability of the Format, with clarifying guidance related to logistical considerations such as a recommended time frame for implementation of Version 4.0, as well as dossier updates and ongoing communication between manufacturers and health care decision makers. The Format should be used as a framework for ongoing evidencebased dialogue between manufacturers and payers. The evolving health care landscape will require new levels of collaboration and communication among key stakeholders to successfully navigate the challenges of this new environment. The Format provides a framework to support these critical interactions related to product value by facilitating an evidence-based, transparent approach.",
author = "{The AMCP Format Executive Committee} and Jeff Lee and Pete Penna and Kim Saverno and Iris Tam and {Daniel Allen}, J. and Avey, {Steven G.} and Diana Brixner and Lin, {Vincent W.} and Malone, {Daniel C} and Newell Mcelwee and Alan Pannier and Sampsel, {Elizabeth R.} and Helen Sherman and John Watkins and Jeffrey White and Susan Oh and Lynn Nishida",
year = "2016",
month = "5",
day = "1",
doi = "10.18553/jmcp.2016.16071",
language = "English (US)",
volume = "22",
pages = "444--446",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "5",

}

TY - JOUR

T1 - The AMCP Format for Formulary Submissions

T2 - Welcome to version 4.0

AU - The AMCP Format Executive Committee

AU - Lee, Jeff

AU - Penna, Pete

AU - Saverno, Kim

AU - Tam, Iris

AU - Daniel Allen, J.

AU - Avey, Steven G.

AU - Brixner, Diana

AU - Lin, Vincent W.

AU - Malone, Daniel C

AU - Mcelwee, Newell

AU - Pannier, Alan

AU - Sampsel, Elizabeth R.

AU - Sherman, Helen

AU - Watkins, John

AU - White, Jeffrey

AU - Oh, Susan

AU - Nishida, Lynn

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Managed care pharmacists are increasingly presented with complex considerations related to prescription drug formulary management. As prescription drug spending soars, and new effective, but expensive drugs rush to the market, pharmacists and other health care decision makers must evaluate a myriad of important clinical and economic considerations in determining the relative value and, subsequently, the appropriate placement of a product within a formulary. The AMCP Format for Formulary Submissions, Version 4.0, is the next iteration of the Format, which was first released in 2000. Version 4.0, developed by pharmacists from health plan, manufacturer, and academic perspectives, provides updated recommendations on acquiring and evaluating clinical and economic evidence to inform formulary and medical policy decisions. It also includes new guidance related to emerging special topic considerations such as biosimilars, specialty pharmacy products, and companion diagnostic tests. Version 4.0 has been modified to improve the usability of the Format, with clarifying guidance related to logistical considerations such as a recommended time frame for implementation of Version 4.0, as well as dossier updates and ongoing communication between manufacturers and health care decision makers. The Format should be used as a framework for ongoing evidencebased dialogue between manufacturers and payers. The evolving health care landscape will require new levels of collaboration and communication among key stakeholders to successfully navigate the challenges of this new environment. The Format provides a framework to support these critical interactions related to product value by facilitating an evidence-based, transparent approach.

AB - Managed care pharmacists are increasingly presented with complex considerations related to prescription drug formulary management. As prescription drug spending soars, and new effective, but expensive drugs rush to the market, pharmacists and other health care decision makers must evaluate a myriad of important clinical and economic considerations in determining the relative value and, subsequently, the appropriate placement of a product within a formulary. The AMCP Format for Formulary Submissions, Version 4.0, is the next iteration of the Format, which was first released in 2000. Version 4.0, developed by pharmacists from health plan, manufacturer, and academic perspectives, provides updated recommendations on acquiring and evaluating clinical and economic evidence to inform formulary and medical policy decisions. It also includes new guidance related to emerging special topic considerations such as biosimilars, specialty pharmacy products, and companion diagnostic tests. Version 4.0 has been modified to improve the usability of the Format, with clarifying guidance related to logistical considerations such as a recommended time frame for implementation of Version 4.0, as well as dossier updates and ongoing communication between manufacturers and health care decision makers. The Format should be used as a framework for ongoing evidencebased dialogue between manufacturers and payers. The evolving health care landscape will require new levels of collaboration and communication among key stakeholders to successfully navigate the challenges of this new environment. The Format provides a framework to support these critical interactions related to product value by facilitating an evidence-based, transparent approach.

UR - http://www.scopus.com/inward/record.url?scp=84969592866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969592866&partnerID=8YFLogxK

U2 - 10.18553/jmcp.2016.16071

DO - 10.18553/jmcp.2016.16071

M3 - Comment/debate

VL - 22

SP - 444

EP - 446

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 5

ER -